Cara Therapeutic (CARA)

Name: Cara Therapeutic (CARA) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Cara Therapeutic (CARA)

Stock Card

$5.32

$-11.33 (-68.05%)

As on 15-Apr-2025 16:00EDT

Market cap

$8 Mln

Revenue (TTM)

$7 Mln

P/E Ratio

P/B Ratio

1.5

Div. Yield

0 %

Cara Therapeutic (CARA) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 5.28 High: 5.52

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-2.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-2.3
Debt to Equity

--
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

1,524,540

10 Years Aggregate

CFO

$-509.24 Mln

EBITDA

$-637.82 Mln

Net Profit

$-619.94 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Cara Therapeutic (CARA)	-71.0	-65.4	-62.0	-80.7	-78.0	-60.1	-35.6
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 15-Apr-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Cara Therapeutic (CARA)	-31.1	-93.1	-11.8	-19.5	-6.1	23.9	6.2
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Cara Therapeutic (CARA)

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the... treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Read more

President, CEO & Director

Mr. Christopher A. Posner
President, CEO & Director

Mr. Christopher A. Posner
Headquarters

Stamford, CT
Website

https://www.caratherapeutics.com

FAQs for Cara Therapeutic (CARA)

What is the current share price of Cara Therapeutic (CARA) Today?

The share price of Cara Therapeutic (CARA) is $5.32 (NASDAQ) as of 15-Apr-2025 16:00 EDT. Cara Therapeutic (CARA) has given a return of -77.98% in the last 3 years.

What is the current PB & PE ratio of Cara Therapeutic (CARA)?

Since, TTM earnings of Cara Therapeutic (CARA) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	--	--
2023	--	--
2022	--	--
2021	--	--
2020	--	--

What is the 52 Week High and Low of Cara Therapeutic (CARA)?

The 52-week high and low of Cara Therapeutic (CARA) are Rs -- and Rs -- as of 28-Aug-2026.

What is the market cap of Cara Therapeutic (CARA)?

Cara Therapeutic (CARA) has a market capitalisation of $ 8 Mln as on 16-Apr-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Cara Therapeutic (CARA)?

Before investing in Cara Therapeutic (CARA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.